Additionally, the oral, irreversible, pan-ErbB tyrosine kinase inhibitor neratinib has been evaluated in patients with previously treated HER2-mutant CCA as part of the SUMMIT basket trial. Here, ERBB2 is linked to cholangiocarcinoma.